Does Rallies show 13F holders for NEO?

Yes. Rallies tracks hedge fund and 13F ownership data for NEO, including fund names, share counts, latest tracked quarter, and position changes when available.

Is NEO research on Rallies investment advice?

No. Rallies provides research, data, and educational context for NEO. It does not provide personalized investment advice.

NEO (NeoGenomics, Inc.) Stock Analysis - Hedge Fund Holdings

NeoGenomics, Inc. (NEO) is a publicly traded Healthcare sector company. As of May 21, 2026, NEO trades at $8.85 with a market cap of $1.09B and a P/E ratio of 0.00. NEO moved +6.08% today. Year to date, NEO is -26.32%; over the trailing twelve months it is +11.39%. Its 52-week range spans $4.72 to $19.12. Analyst consensus is buy with an average price target of $14.94. Rallies surfaces NEO's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns NEO stock?

Hedge funds tracked by Rallies that own NEO include Bridgewater Associates, Mangrove Partners, and Farallon Capital. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for NeoGenomics, Inc..

NEO Key Metrics

Key financial metrics for NEO
Metric	Value
Price	$8.85
Market Cap	$1.09B
P/E Ratio	0.00
EPS	$0.00
Dividend Yield	0.00%
52-Week High	$19.12
52-Week Low	$4.72
Volume	4.23K
Avg Volume	0
Revenue (TTM)	$727.33M
Net Income	$-108.03M
Gross Margin	43.21%

Top Hedge Funds Holding NEO

Bridgewater Associates holds 91.19K shares of NEO, changed +533.40% as of Mar 31, 2026.
Mangrove Partners holds 87.94K shares of NEO, changed +0.00% as of Jun 30, 2025.
Farallon Capital holds 19.00K shares of NEO, changed +0.00% as of Mar 31, 2026.

Latest NEO News

NeoGenomics Debuts RaDaR ST Assay for Residual Disease in Breast, Lung, Colorectal Tumors — Feb 25, 2026
NeoGenomics Down 22.8%, RSI 26.14 Signals Oversold, EPS Estimates Up 14.8% — Feb 20, 2026
NeoGenomics Reports 10% Revenue Growth to $727M Despite -$0.84 FY EPS — Feb 17, 2026
NeoGenomics Unveils PanTracer Pro with 500-Gene Profiling and 8-10 Day Turnaround — Feb 16, 2026
NeoGenomics Q3 Revenue Jumps 11.9% to $187.8M, Q4 Revenue Forecast at $188.3M — Feb 16, 2026

Recent NEO Insider Trades

Stone Warren sold 22.13K (~$276.68K) on Jan 20, 2026.
Olivo Alicia C sold 20.92K (~$250.99K) on Nov 25, 2025.
Olivo Alicia C sold 4.92K (~$49.18K) on Oct 16, 2025.

NEO Analyst Consensus

11 analysts cover NEO: 0 strong buy, 8 buy, 3 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $14.94.

Common questions about NEO

Who owns NEO stock?: Hedge funds tracked by Rallies that own NEO include Bridgewater Associates, Mangrove Partners, and Farallon Capital. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for NeoGenomics, Inc..
Does Rallies show 13F holders for NEO?: Yes. Rallies tracks hedge fund and 13F ownership data for NEO, including fund names, share counts, latest tracked quarter, and position changes when available.
Is NEO research on Rallies investment advice?: No. Rallies provides research, data, and educational context for NEO. It does not provide personalized investment advice.